The missed EPS estimate could negatively impact investor sentiment in the short term, suggesting potential downward pressure on PRCT's stock price. However, the significant sales beat and year-over-year growth could counterbalance this by highlighting the company's growing market presence and potential for future profitability. The mixed nature of the report makes the short-term stock price direction uncertain, hence a neutral score.